Physician profile
Renee Ruth Lamm
NPI 1245214592
$1,266,798.48
in general payments reported to CMS, 2019-2025
31 companies · $261K in 2025
The $261K reported for 2025 was more than what 99% of Addiction Psychiatry providers received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $109K · 2020: $61K · 2021: $141K · 2022: $167K · 2023: $315K · 2024: $212K · 2025: $261K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $434K · Consulting Fee: $171K · Honoraria: $100K · Travel and Lodging: $63K · Food and Beverage: $20K · Education: $54.13.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $434,214.60 |
| Consulting Fee | $170,778.00 |
| Honoraria | $99,743.00 |
| Travel and Lodging | $63,490.07 |
| Food and Beverage | $20,006.30 |
| Education | $54.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $419,498.16 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Axsome Therapeutics, INC. | $305,849.79 | 2022-2025 | Auvelity, Sunosi |
| Teva Pharmaceuticals USA, INC. | $175,814.16 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Abbvie INC. | $155,231.44 | 2021-2025 | |
| Alkermes, INC. | $107,053.10 | 2019-2025 | Lybalvi, Vivitrol, Vivitrol |
| Allergan, INC. | $45,490.34 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $17,785.50 | 2019-2025 | Fanapt, Hetlioz |
| Janssen Pharmaceuticals, INC | $10,481.18 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Neurocrine Biosciences, INC. | $9,964.74 | 2019-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $7,713.44 | 2019-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $6,568.23 | 2021-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $2,332.28 | 2019-2022 | |
| Lundbeck LLC | $476.74 | 2019-2025 | Rexulti |
| Corium, LLC | $358.53 | 2022-2024 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $355.71 | 2024-2025 | Cobenfy |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $351.44 | 2019-2025 | Rexulti |
| Ironshore Pharmaceuticals INC. | $335.62 | 2019-2024 | Jornay Pm |
| Tris Pharma INC | $189.47 | 2020-2025 | Dyanavel Xr |
| Adlon Therapeutics L.P. | $173.09 | 2019-2021 | |
| Indivior INC. | $160.96 | 2019-2025 | Sublocade |
| Supernus Pharmaceuticals, INC. | $111.37 | 2022-2025 | Qelbree, Qelbree |
| Avanir Pharmaceuticals, INC. | $105.95 | 2019 | |
| Bausch Health US, LLC | $98.08 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $87.21 | 2019-2020 | |
| Collegium Pharmaceutical, INC. | $78.59 | 2025 | Jornay Pm |
| Shire North American Group INC | $38.36 | 2019 | |
| Idorsia Pharmaceuticals US INC | $29.83 | 2022-2023 | Quviviq |
| Neos Therapeutics, Lp | $26.02 | 2020-2024 | Adzenys Xr-Odt |
| Lilly USA, LLC | $15.09 | 2025 | Zepbound |
| Arbor Pharmaceuticals, INC. | $12.65 | 2019 | |
| Eisai INC. | $11.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Renee Lamm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.